Human epidermal growth factor receptor 2 (HER2, ERBB2) mutations serve as oncogenic drivers in a limited fraction of NSCLCs, with occurrence rates of 2–3% among general NSCLC patients and up to 6.7% in patients negative for EGFR/ALK/ROS1.132, 133, 134. Here, EGFR is linked to non-small cell lung carcinoma.